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Reduced mechanistic target of rapamycin (mTOR) signalling extends lifespan in yeast, 20 
nematodes, fruit flies and mice, highlighting a physiological pathway that could modulate 21 
aging in evolutionarily divergent organisms. This signalling system is also hypothesised to 22 
play a central role in lifespan extension via dietary restriction. By collating data from 48 23 
available published studies examining lifespan with reduced mTOR signalling, we show that 24 
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genetic mTOR manipulations consistently providing greater life-ext nsion than 26 
pharmacological treatment with rapamycin. In contrast to the consistency in hanges in 27 
median lifespan, however, the demographic causes for life-extension are highly species-28 
specific. Reduced mTOR signalling extends lifespan in nematodes by strongly reducing the 29 
degree to which mortality rates increase with age(aging rate). By contrast, life-extension in 30 
mice and yeast occurs largely by pushing back the onset of aging, but not altering the shape 31 
of the mortality curve once aging starts. Importantly, in mice, the altered pattern of mortality 32 
induced by reduced mTOR signalling is different to that induced by dietary restriction, which 33 
reduces the rate of aging. Effects of mTOR signalling were also sex-dependent, but only 34 
within mice, and not within flies, thus again species-specific. An alleviation of age-associated 35 
mortality is not a shared feature of reduced mTOR signalling across model organisms, and 36 
does not replicate the established age-related survival benefits of dietary restriction.  37 
 38 
Introduction 39 
Rapamycin and closely-related analogues are considered the most promising treatments for 40 
aging and age-related disease available for translation to humans (Johnson et al. 2013). 41 
Rapamycin exerts its effects by inhibiting signalling of the mechanistic target of rapamycin 42 
(mTOR) pathway. Although mTOR is present in two distinct complexes, rapamycin 43 
preferentially inhibits mTOR complex 1 (mTORC1) (Stanfel et al. 2009), with direct genetic 44 
reductions of mTORC1 activation also extending lifespan (e.g. Jia et al. 2004; Kapahi et al. 45 
2004; Kaeberlein et al. 2005; Lamming et al. 2012). The physiological effects of reduced 46 
mTORC1 activation, particularly the decline in cellular growth and elevated organismal 47 
survival, are expected to be a consequence of downstream inhibitory effects on several 48 
mTORC1 substrates, particularly the ribosomal S6 kinase (S6K), which has been most 49 
intensively studied (Gems & Partridge 2013). S6K controls protein translation, and can 50 
feedback to influence other pathways linked to nutritional status, such as insulin signalling 51 
and adenosine monophosphate protein kinase (AMPK) (Selman et al. 2009). Decreased S6K 52 
activation is hypothesised to be a major cause of lifespan-extension through genetically or 53 
pharmacologically reduced mTORC1 activation (Hansen et al. 2007; Gems & Partridge 54 
2013; Johnson et al. 2013). 55 
Pharmacological treatment with rapamycin, genetic impairments of the mTORC1 complex, 56 
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pathway. Indeed, separate manipulations of each of these components have been shown to 58 
extend lifespan in the four most popular animal models in aging research: Sacchromyces 59 
cerevisiae (yeast), Caenorhabditis elegans (nematodes), Drosophila melanogaster (flies), and 60 
Mus musculus (mice) (Johnson et al. 2013). Although seemingly universal across species, 61 
there are several factors that might influence the degree of lifespan extension within and 62 
between species. In both mice and flies, manipulations of mTOR signalling have been 63 
reported as sex-dependent, preferentially improving female lifespan over that of males 64 
(Bjedov et al. 2010; Miller  et al. 2014). In flies, one study reported that rapamycin can 65 
decrease lifespan at high concentrations (Harrison et al. 2010), while in mice lifespan 66 
extension has been positively associated with rapamycin concentration (Miller  et al. 2014). 67 
Different manipulation types (e.g. rapamycin, genetic manipulations of mTORC1 or S6K) 68 
may also have physiological effects that influence survival outside of this simplified pathway, 69 
leading to possible differences in the degree of lifespan extension: examples include the 70 
possible inhibitory effects of rapamycin on mTORC2 (Lamming et al. 2012), and the 71 
additional regulatory effects of mTORC1 signalling on translation initiation factors in 72 
addition to S6K (Johnson et al. 2013).  73 
Although manipulations of the mTOR complex can extend median lifespan, there is relatively 74 
little understanding of the demographic pathways through which this life-extension occurs. 75 
Longer lifespans of animals with reduced mTOR signalling, compared to control animals, 76 
could occur because of various alterations of age-specific mortality rate. For a manipulation 77 
to slow aging, in a demographic sense, it is expected to reduce the rate at which mortality 78 
increases in a population over time (Good & Tatar 2001; Mair et al. 2003; Simons et al. 79 
2013). This is usually assessed by fit ting Gompertz (m(t)= a + exp(bt) ) models (Figure 1), 80 
which separate Parameter b, the “aging rate” of the population (the rate of increase in 81 
mortality with age), and parameter a, which describes the vulnerability to dying at a similar 82 
level of somatic damage (Simons et al. 2013; Kirkwood 2015). Individual studies in mice 83 
have suggested that changes in either of these parameters could potentially be responsible for 84 
lifespan extension with rapamycin (Miller  et al. 2011; Fok et al. 2014), although limitations 85 
in sample size in each case have hampered the ability to draw firm conclusions about the 86 
cohort under study.   87 
To understand the consistency and demographic causes of lifespan extension via reduced 88 
mTOR signalling, we collated data from previous lifespan experiments conducted in mice, 89 
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control-treatment comparisons. We analysed this dataset using meta-an lysis for both life 91 
extension – measured at median lifespan of the controls (HR50
Results  102 
) – and the resulting 92 
demographic trajectory in terms of changes in mortality over different periods of life. By 93 
using such a large-scale approach, we were able to statistically test whether lifespan 94 
extension with particular genetic manipulations mimics the mortality effects observed with 95 
pharmacological treatment with rapamycin, and even whether reduced mTOR signalling 96 
mimics the changes in mortality that occur with dietary restriction. We were also able test 97 
whether lifespan extension is similar across species – and thus whether changes in mortality 98 
in shorter-lived and simpler organisms predict changes in longer-lived and more complex 99 
organisms – and whether different types of manipulation provide similar survival benefits to 100 
males and females. 101 
Reduced mTOR signalling consistently extends lifespan 103 
Treatment with rapamycin, genetic manipulation of components of the mTORC1 complex, or 104 
deletion of the mTORC1 substrate S6K together generate an overall lifespan extending effect, 105 
when these collated data are analysed using meta- nalysis (HR50 = -0.55, -0.66:-0.44 95%CI; 106 
Figure 2A; Tables S1 & S2). Mice, flies, nematodes and yeast show a similar level of lifespan 107 
extension in response to reduced mTOR signalling (QM
Soukas et al. 2009
(df=3)= 3.78, p = 0.29, Table S2). 108 
Genetic manipulation of the mTORC1 complex, or S6K, (manipulation of these two targets 109 
have similar effects on lifespan, β = -0.08 ±0.09(s.e), p = 0.37) generates a stronger increase 110 
in median lifespan (β = -0.25 ±0.09(s.e), p = 0.006) than pharmacological treatment with 111 
rapamycin (Figure 2A; Table S2). This greater life-extension with genetic manipulations 112 
might be the result of several factors. One possibility is that rapamycin might have effects 113 
outside of reducing mTORC1 signalling that have some counteracting detrimental on 114 
survival, reducing the life-extension of rapamycin-treated animals to below that observed 115 
with genetic manipulations. The weaker inhibitory effects of rapamycin on mTORC2 116 
signalling are of particular note, since reduced activity of this complex can sometimes reduce 117 
lifespan ( ; Lamming et al. 2014), and has been linked to the generation of 118 
insulin resistance in rapamycin treated mice (Lamming et al. 2012). 119 
Smaller life-extension with rapamycin compared to genetic manipulations might also be a 120 
consequence of administration of suboptimal rapamycin concentration doses(Ka berlein 121 
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different concentrations of rapamycin have only been investigated in a si gle study in mice 123 
(Miller  et al. 2014), with the majority of other studies using a dietary treatment regime at a 124 
concentration of 14ppm (see supplementary data). This precludes a meta-analysis of a 125 
concentration effect within mice. It is, however, notable that the lifespan extension achieved 126 
at the highest concentration of rapamycin employed in mice (Miller  et al. 2014) is at least 127 
similar, if not slightly greater, than the average effect achieved through the various genetic 128 
manipulations of the TOR pathway in mice (model comparing mouse lifespan at the highest 129 
rapamycin concentration to mouse lifespan with genetic manipulation f TOR or S6K: β = -130 
0.38±0.21(s.e), p = 0.07). The limited data available in flies (only two studies have examined 131 
lifespan at different rapamycin concentrations) also suggests previous treatment 132 
concentrations may be suboptimal for maximising lifespan extension, although in this case 133 
the relationship between treatment concentration and lifespan extension is negative (β = 134 
0.025±0.011(s.e), p = 0.018), highlighting that rapamycin at high doses may be toxic to this 135 
species (Harrison et al. 2010). 136 
Impacts on demographic mortality are species-specific 137 
To understand how mTOR-related pharmacological and genetic manipulations influence the 138 
demography of mortality, we calculated the Gompertz parameters for each experimental 139 
replicate using maximum likelihood (Promislow et al. 1999; Simons et al. 2013). Given the 140 
incongruity in concentration of rapamycin we selected within each study the concentration 141 
that achieved the greatest life extension (based on HR50
Lamming et al. 2012
). Additionally, in one case 142 
( ) some manipulations of different components of the mTORC1 143 
complex did not appear to reduce mTORC1 signalling, therefore we also excluded those 144 
specific comparisons. We took this approach because we wer  interested in how mTOR 145 
signalling regulates the demography of mortality, rather than in estimating an overall effect 146 
across all available effect sizes. 147 
Gompertz is a simple but effective model (Pletcher 1999; Simons et al. 2013; Kirkwood 148 
2015) to separate the two main demographic parameters of mortality. A decline in b, the age 149 
dependent factor, is expected if a treatment reduces the rate of aging, rather than protecting 150 
against factors that reduce age-d pendent mortality across the life course (a: vulnerability, 151 
also known as: frailty, initial mortality rate). In a strong contrast to the effects of mTOR 152 
signalling on median lifespan, changes in both demographic parameters are largely consistent 153 
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& S3). In nematodes, lifespan extension is associated with a strong reduction in parameter b 155 
(Figure 3B), the rate of aging, without effects on parameter a (Figure 3A). In mice, flies and 156 
yeast, lifespan extension is more closely associated with a reduction in parameter a (Figure 157 
3A), reducing the vulnerability to mortality across the life course. The overall predicted 158 
survival and mortality trajectories for each species are provided in Figures 3C & D. 159 
Female lifespan extension is consistently greater in mice but not flies 160 
It has been reported that reduced mTOR signalling can have a stronger lifespan impact on 161 
females than males, in both mice and flies treated with the drug rapamycin (Bjedov et al. 162 
2010; Miller  et al. 2014) and in S6K and mTORC1 component knockout mice (Selman et al. 163 
2009; Lamming et al. 2012). It has also been noted, in mice, that the activity of the mTORC1 164 
complex can differ between sexes (Drake et al. 2013; Baar et al. 2016), and that any 165 
concomitant reductions in mTORC2 signalling with rapamycin treatment can have greater 166 
detrimental effects on males (Lamming et al. 2014). We tested whether there is a consistent 167 
sex-bias in lifespan-extension with reduced mTOR signalling and found that the sex bias in 168 
lifespan response is species-dependent (Table S3, Figure 2A). Only in mice, but not in flies, 169 
does reduced mTOR signalling increase lifespan to a greater extent in females than males 170 
(Figure 2A). It has been suggested that the sex- pecific response to rapamycin in mice is a 171 
consequence of differences in metabolism of this drug in males and females (Mil r  et al. 172 
2014). However, there is no evidence for a differing effect of sex in those studies that 173 
manipulated mTOR signalling through pharmacological (rapamycin) or genetic means in 174 
mice (Table S3). This result further highlights that there are biological differences between 175 
the sexes unrelated to drug metabolism, and potentially unrelated to rapamycin’s effects on 176 
mTORC2, that determine lifespan responses toreduced mTOR signalling. 177 
Lifespan extension by reduced mTOR signalling and DR are distinct  178 
Reduced mTOR signalling is predicted to play a central role in lifespan extension via dietary 179 
restriction (DR) (Kennedy et al. 2007; Kaeberlein 2014). However, epistasis studies in 180 
different species have produced mixed results (Kapahi et al. 2004; Kaeberlein et al. 2005; 181 
Bjedov et al. 2010; Ching et al. 2010), and in mice rapamycin treatment and DR generate 182 
distinct changes in physiology (see discussion for examples). When comparing our results on 183 
the demographic pathways of lifespan extension with reduced mTOR signalling to a recent 184 
study examining the demographic pathway to life-extension in rodents via DR (Simons et al. 185 
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signalling occurs predominately through a reduction in parameter a, while lifespan extension 187 
via DR in rodents – although variable in its demographic response (Merry 2005; and figure 4) 188 
– occurs predominately through a reduction in parameter b (Simons et al. 2013). Biologically, 189 
reduced mTOR signalling appears to increase resilience to aging-related mortality, while DR 190 
reduces the increase in mortality rate that occurs as animals grow older. 191 
To quantitatively test whether DR and reduced mTOR signalling affect mouse lifespan via 192 
differential alteration of gompertz parameters, we combined mouse lifespan data from the 193 
current meta-analysis with a previous meta-analysis on DR (Simons et al. 2013). There was 194 
no statistical difference between the change in parameter a under DR and that induced with 195 
reduced mTOR signalling in mice (QM
Simons et al. 2013
(df = 1) = 1.73, p = 0.19; Figure 4, Table S1), despite 196 
an apparent stronger effect on a when mTOR is manipulated (estimates from separate 197 
models: DR: 0.31, -0.34:0.96 95%CI, mTOR: -0.42, -0.77:-0.06 95%CI). The lack of a 198 
statistical difference is probably attributable to the substantial variation in the effect of DR on 199 
this parameter ( ); this heterogeneity is only partly explained by differences 200 
in response between strains (see Table S4). By contrast, only DR consistently reduces the rate 201 
of aging (estimates from separate models: DR: -0.29, -0.39:-0.18 95%CI, mTOR: -0.016, -202 
0.10:0.07 95%CI), with mice showing a significantly different response in this aging-203 
parameter depending on whether they receive a treatment that reduces mTOR signalling or 204 
whether they are dietary restricted (QM(df = 1) = 8.43, p = 0.004). Thus, at least with regards 205 
to the way these to treatments influence age-related mouse mortality, the effects of these 206 
treatments are distinct. This demographic perspective provides additional insight over 207 
conventional measures such as the effect on median lifespan, for which the two treatments do 208 
not significantly differ (QM(df = 1) = 1.19, p = 0.28, Figure 4). Notably, hardly any 209 
heterogeneities among studies were observed in both aging parameters, a and b with reduced 210 
mTOR signalling (less than 29% for both) whereas for DR, much of the variation seemed to 211 




 = 63.4%; Table S1). This result 212 
suggests that reduced mTOR exerts much more stable and reliable life-extending effects in 213 
mice than DR.  214 
The mTORC1 signalling complex ishighly responsive to nutrients, and consequently DR is 216 
expected to reduce the activity of this complex (Johnson et al. 2013). Since reduced mTOR 217 
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DR mimic (Longo et al. 2015). While both do extend lifespan, we show here that reduced 219 
mTOR signalling does not mimic the age-related survival benefits of DR, adding to a 220 
growing picture of distinctiveness of these two life-span extending interventions.  This is not 221 
to say that reduced mTOR signalling is not important in the DR-response – it might still be 222 
indispensable for DR-mediated lifespan extension i  mice and play an important role in the 223 
improvement of mouse survival. However, our results indicate that the differential effects of 224 
these two treatments on certain aspects of physiology (for example, insulin sensitivity (Fok et 225 
al. 2013), fat deposition (Fok et al. 2013), xenobiotic metabolism (Miller  et al. 2014), fatty 226 
acid oxidation (Yu et al. 2015) and mitochondrial biology (Fok et al. 2014; Karunadharma et 227 
al. 2015) are likely influencing at least some of the factors that influence mouse death, either 228 
their probability of occurrence or age at onset, generating these distinct mortality patterns that 229 
we observe. 230 
Epistasis studies in mice may further help to determine whether DR provides aging benefits 231 
outside of mTOR signalling, although an epistatic interaction for lifespan does not 232 
necessarily indicate that one pathway plays a causal role in generating the survival benefits of 233 
the other, particularly if the phenotypes of the twom dels (e.g. DR and mTOR manipulation) 234 
are dissimilar (Hekimi et al. 2001). DR-mTOR epistasis studies, in other organisms, have 235 
additionally produced mixed results. In yeast and worms, DR failed to extend lifespan of 236 
either mTOR or S6K mutants (Kaeberlein et al. 2005), but in flies rapamycin treatment is still 237 
able to extend the lifespan of DR individuals (Bjedov et al. 2010). Rapamycin treatment in 238 
flies also seems to block the n gative effects that essential amino acid supplementation has on 239 
DR-mediated life-extension (Emran et al. 2014). While these discrepancies might partly 240 
occur because of the use of different DR regimes, which can have different gene-241 
dependencies (Greer & Brunet 2009), it hints that the importance of mTOR in DR-mediated 242 
lifespan extension might vary in different organisms.  243 
The comparison of mortality effects of reduced mTOR signalling across model organisms 244 
highlights that, while generating consistent changes in average lifespan, impacts on mortality 245 
demographic parameters differ between species. In mice, yeast and (although non-significant) 246 
in flies, mTOR signalling reduced vulnerability to age-dependent mortality, a. In contrast, 247 
reduced mTOR signalling in nematodes generates a strong reduction in the rate of aging, b. It 248 
is notable that the species examined here do not always show extended lifespan through 249 
alteration in these specific Gompertz parameters. In flies, genetic, dietary and temperature 250 
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1999), highlighting that changes in lifespan can occur through alteration in either Gompertz 252 
parameter. In nematodes, different long-lived mutants show wide-ranging changes in both 253 
Gompertz parameters (Johnson et al. 2001). Recent large scale demographic experiments in 254 
C. elegans have shown that manipulations of temperature, oxidative stress, diet, heat shock 255 
response and the insulin/IGF-1 pathway all affect the scaling of the survival curve, analogous 256 
to vulnerability in the Gompertz (Stroustrup et al. 2016). Stroustrup et al. suggest that this 257 
scaling pattern is therefore invariant across lifespan-extending manipulations, but the results 258 
presented here suggest that mTOR manipulation actually has a very contrasting demographic 259 
effect in this species, warranting further direct experimental comparison. In mice, DR can 260 
influence aging rate while many genetic aging models show a change in vulnerability to age-261 
related death (a) (de Magalhães et al. 2005). We therefore conclude that these species-262 
specific responses to reduced mTOR signalling are a consequence of underlying biological 263 
differences between these model organisms in the way reduced mTOR signalling affects 264 
mortality and associated physiological pathways at different periods of life. 265 
The specific change that is observed in the demography of mortality provides a fundamental 266 
insight into how a particular treatment influences the probability of death, both at an 267 
immediate point in time, at future time points after the treatment is discontinued, or if only 268 
started late in life. A reduction in the rate of aging, as observed with reduced mTOR 269 
signalling in C elegans, is expected to be linked to permanent alterations in age-associated 270 
damage and dysfunction (Jacobson et al. 2010), such that discontinuing the treatment would 271 
still leave an individual with improved survival prospects (Mair et al. 2003). By contrast, 272 
changes to vulnerability (a) are predicted to be reversible, in that current mortality is 273 
dependent on the current dietary or drug regime, without any carryover effects, as shown for 274 
DR in flies (Mair et al. 2003). It is notable that the degree of lifespan extension via DR in 275 
mice is strongly dependent on the age at which treatment starts, consistent with an effect on 276 
aging rate (Simons et al. 2013). Rapamycin treatment seems to extend lifespan to a similar 277 
degree irrespective of whether treatment starts early in life or at middle-age (Miller  et al. 278 
2011; Table S5), consistent with the effect on the vulnerability to mortality we report here. 279 
This difference in the age-dependence of these two treatments further supports the argument 280 
that these two manipulations have distinct impacts on mouse mortality and the biology of 281 
aging. Treatments that reduce age-independent mortality in humans and mice are predicted to 282 
be able to provide the full survival benefits to an individual regardless of when the treatment 283 
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stable impacts on physiology and mortality as it has shown here in mice, the health and 285 
survival benefits accrued from treatments starting late in life may still be substantial.  286 
The meta-analytical approach we use here, allowing comparison of lifespan extension and 287 
changes in mortality rates through genetic, dietary and pharmacological treatments, provides 288 
a comparative technique to help adjudicate the consistency (and distinctiveness) of treatments 289 
that might slow aging across species. The consistency in lifespan extension, in a demographic 290 
sense, via genetic manipulations of mTOR signalling and pharmacological treatment with 291 
rapamycin, within species, matches the view that these treatments operate through the same 292 
physiological/molecular pathway. However, the different responses across species highlights 293 
that effects on age-specific mortality are dependent on the biological system, insights that 294 
remained hidden in single smaller sample sized studies on one organism. Further focussed 295 
empirical studies will help to confirm these differential impacts on death experimentally. For 296 
example, since rapamycin treatment influenced the rate of aging in ematodes, but age-297 
independent mortality in yeast, experiments where rapamycin treatment is started or stopped 298 
part way through life (as conducted by Mair et al. (2003) and Merry et al. (2008)  for DR in 299 
fruit flies and rats respectively) will reveal whether these differences in Gompertz parameters 300 
of mortality do translate to permanent/transient impacts on mortality rates on an inter-species 301 
scale. Such experiments will also help to confirm whether the observed differences in 302 
mortality parameters reflect underling differences in how reduced mTOR signallin  effects 303 
somatic damage and dysfunction linked to aging and vulnerability to death. 304 
 305 
Experimental procedures 306 
Search protocol 307 
The search protocol was based on that used in previous meta-analyses of lifespan extension 308 
(Hector et al., 2012; Nakagawa et al., 2012). Studies were including on model species 309 
considered to be wild-type – without additional genetic manipulation or particular 310 
susceptibility to disease – and where gene expression was manipulated across all tissues. We 311 
included all genetic manipulations that inhibited the activity of the mTORC1 complex or 312 
downstream S6K. The supplementary dataset shows the specific manipulation used in each 313 
study. 314 
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Raw individual survival data was used whenever possible. When unavailable, mortality was 316 
measured from survival curves. Gompertz models were then fitted using maximum likelihood 317 
estimation (Pletcher 1999), and estimates of sampling variances were obtained either from 318 
the confidence intervals around the parameters fitted on the individual level data, or estimated 319 
through simulation (Simons et al. 2013). To assess overall effects on lifespan a hazard ratio at 320 
median lifespan was calculated using the number of individuals died and at risk in both 321 
experimental groups, for which sampling variances are known (Nakagawa et al. 2012). Meta-322 
analyses were run on these hazard ratios at median lifespan and the hazard ratio of the two 323 
Gompertz parameters with treatment group (reduced TOR signalling) over the control group - 324 
negative hazard ratio estimates indicate improved survival. Mixed effects meta-analyses were 325 
conducted using the package ‘metafor’ (Viechtbauer 2010) in R (Team 2006). Study was 326 
included as random term and because in some cases a control group was used as comparison 327 
to multiple treatment groups we modelled such data dependence using a covariance matrix. 328 
Heterogeneity in meta- nalyses was assessed by a multilevel version of I2 Nakagawa & (329 
Santos 2012). We tested for publication and reporting bias (see supplementary material) 330 
using rank tests of sample size against effect size and did not detect any significant bias apart 331 
from one case (Table S6); however, it was one out of 30 tests and it is within the expected 332 
Type I error rate (0.05). This result suggests that our meta-analytic outcomes and conclusions 333 
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 351 
Figure legends 352 
 353 
Figure 1. Schematic overview of the resulting survival (a) and mortality trajectories  (b) 354 
when the Gompertz parameters a (vulnerability) and b (aging rate) are varied independently. 355 
Compared to a control condition (solid lines) a similar lifespan extension as meured at 356 
median lifespan either through a change solely in a (short dash) or b (long dash) is drawn. 357 
 358 
Figure 2. Forest plots of effect size for the logarithm of the hazard ratio (ln(HR)) for changes 359 
in median lifespan and mortality parameters with reduced mTOR signalling. Data is 360 
synthesised from 155 different control-treatment comparisons (see supplementary data file). 361 
Bars show the effect size with 95% confidence intervals for treatment changes in median 362 
lifespan (A), vulnerability to aging (B) and rate of aging (C). Within each plot the estimated 363 
overall effect sizes using meta-analysis are shown across all effect sizes, separating 364 
pharmacological (rapamycin) and genetic manipulations of mTORC1 and S6K signalling, 365 
and separated per sex where applicable. Overall ffects are reported across species, included 366 
species in addition to study as a random term. Overall estimates of these categories (see 367 
legend) and their 95% confidence intervals are provided, with data from all specie  368 
combined, in addition to results for each individual species. 369 
 370 
Figure 3. Bubble plots showing the raw data of the Gompertz parameters per species with the 371 
control plotted against reduced mTOR signalling (A & B). Bubble area reflects differences in 372 
sample size of the experimental group (circles represent males, squares represent females). 373 
Below the diagonal (shaded blue) indicates a reduction of mortality risk via this parameter. 374 
Predicted overall survival (C) and mortality trajectories (D) are provided in the right two 375 
columns. These represent the meta- nalytic mean of both Gompertz parameters of the 376 
controls (yellow lines) adjusted for the meta-analysed hazard ratio of this parameter under 377 
reduced TOR signalling (blue lines). Dashed lines indicate females. Within mice, flies and 378 
yeast, extension in lifespan via reduced TOR signalling is a result of a demographic change in 379 
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nematodes this is the result of a change in Gompertz parameter b (i.e. aging rate, the slope of 381 
mortality).  382 
Figure 4. Overall effects of reduced TOR signalling (open dots) on median lifespan, 383 
vulnerability (a) and aging rate (b) in mice versus those parameters under DR. Effects and 384 
95% confidence intervals represent effects from separate meta-analyses. The life extension 385 
from DR results from a change in ageing rate, versus a change in vulnerability under reduced 386 
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